Study LIFE: New Prospects for the Use of Losartan
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Результаты двойного слепого рандомизированного исследования LIFE, включавшего свыше 9 тыс. больных с артериальной гипертензией (АГ) и ГЛХ, показали, что антагонист рецепторов ангиотензина II 1-го типа лозартан при длительном применении (в среднем 4,8 года) снижает комбинированный риск сердечно-сосудистых осложнений на 13% по сравнению с β-адреноблокатором атенололом. Особенно заметно при этом уменьшался риск инсульта. Помимо этого лозартан на 25% снижал риск возникновения новых случаев сахарного диабета. Превосходство лозартана над атенололом проявлялось при сходном антигипертензивном действии.
Особенно выраженным протекторное действие лозартана было у больных с сопутствующим сахарным диабетом. У этой категории пациентов он, по сравнению с атенололом, снижал комбинированный риск сердечно-сосудистых осложнений на 24%. Это сопровождалось снижением общей смертности на 39%.
Лозартан стал первым и пока единственным лекарственным средством, достоверно превосходящим стандартный препарат для лечения АГ, с точки зрения профилактики неблагоприятных кардиоваскулярных исходов. В настоящее время обсуждаются возможные механизмы действия и перспективы применения лозартана в широкой медицинской практике.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Neil B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drug: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000;356:1955-64.
Burt VL, Whelton P, Roccella EJ. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988;1991. Hypertension 1995;25:305-13.
Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC;VI). Arch Intern Med 1997;157:2413-46.
Danlof B, Devereux RB, Kieldsen SE, et al, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001;104:1615-21.
Brunner HR. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol 2001;87(8A):C3-9.
Dahlof B, Pennert K, Nansson L. Reversal of left ventricular hypertrophy in hypertensive patients – a meta-analysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
Dahlof B. Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens 2001;14:174-82.
Yusuf S, Sleight P, Pogue J, et al. Effects of an angitensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.
Timmermann PB. Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertens Res 1999;22:147-53.
Dahlof B, Keller SE, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995;8:578-83.
Murlow C, Lau J, Cornell J, Brand M. Pharmacotherapy for hypertension in the elderly (Cochrane review). In: The Cochrane Library, Issue 2, 2001. Oxford: Update Software.
First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;2:57-66.
Lindholm LH, Ibsen H, Danlof B, et al, for the LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.
Kjeldsen SE, Julius S, Hedner T, Hansson L. Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomised intervention trials. Blood Pressure 2001;10:1-3.
Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986;57:F43-9.
Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-5.
Gorelic PB. Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy. Stroke 2002;33:862-75.
Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetic epidemic. Nature 2001;414:782-7.
Kannel WB, McGee DL. Diabetes and cardiovascular risk factors in the Framingham study. Circulation 1979;59:8-13.
Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older patients with isolated systolic hypertension. JAMA 1996;276:1886-92.
Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999;353:611-6.
UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 39. BMJ 1998;317:713-21.
Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertension 1999;12(suppl.):S205-13.
Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation 2000;101:2271-6.
JN, Devereux RB, Roman MJ, et al. Separate and joint effects of hypertension and diabetes mellitus on left ventricular structure and function: the Strong Heart Study. Am J Cardiol 2001;87:1260-5.
Liu JE, Palmieri V, Roman MJ, et al. Cardiovascular disease and prognosis in adults with glucose disorders: the Strong Heart Study. J Am Coll Cardiol 2000;35:363A [abstract].
Brenner BM, Cooper ME, de Zeeuw D, et al, for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
